This is an automatically translated article.
Zoldal drug with the main ingredient is zoledronic acid, used to prevent bone-related phenomena such as pathological fractures, hypercalcemia due to cancer, radiation or bone surgery, spinal compression, bone cancer ,... Let's find out more details about how to use and the notes when using Zoldal through the article below.
1. What is Zoldal?
Zoldal drug belongs to the group of anti-cancer drugs and affects the immune system, made in the form of lyophilized powder for injection and packaged in a box of 1 plastic tray 1 vial of 4mg.
Zoldal drug has the main ingredient zoledronic acid (in the form of zoledronic acid monohydrate) content of 4mg and other excipients.
2. What disease does Zoldal treat?
Zoldal drug is used in the following cases:
Preventing bone-related phenomena such as pathological fractures, hypercalcemia due to cancer, radiation or bone surgery, spinal compression in cancer patients including bone cancer. Treatment of blood calcium due to cancer. Patients need to strictly follow the instructions for using Zoldal in accordance with the indications on the use and function for each subject listed on the Zoldal instruction sheet or the doctor's prescription sheet.
3. Dosage - How to take Zoldal
Prevent bone-related phenomena in advanced cancer patients.
Adults and the elderly: The recommended dose is 4 mg of zoledronic acid in a reconstituted Zoldal solution and further dilution for infusion (dilute with 100 ml of 0.9% w/v NaCl or 5% glucose solution by volume/volume), intravenous infusion of Zoldal with a time of at least 15 minutes, 3-4 times. Patients need to be supplemented with 500mg of calcium and 400IU of vitamin D per day. Use Zoldal drug to treat hypercalcemia in malignant tumors
Adults and elderly: The recommended dose is to use 4mg of zoledronic acid in a prepared solution and continue to be diluted for infusion, intravenous infusion of reconstituted Zoldal drug. during 15 minutes. The patient must be adequately rehydrated before and during treatment. It is necessary to apply the exact dose of Zoldal indicated on the package, the drug leaflet or the instructions of the doctor or pharmacist. Patients do not arbitrarily calculate, apply or change the dose of Zoldal.
4. Contraindications to the use of Zoldal
Zoldal should not be used in the following cases:
The patient is allergic to any of the ingredients of Zoldal. Women in pregnancy. Breastfeeding mothers. Do not take Zoldal concomitantly with other bisphosphonates.
5. Zoldal drug interactions
To avoid possible drug interactions, the reconstituted Zoldal solution should be diluted with a 0.9% w/v NaCl solution or a 5% w/v glucose solution.
Reconstituted Zoldal solution must not be mixed with infusion solutions containing calcium or divalent cations, such as Lactated Ringer's solution, and Zoldal must be infused by a separate infusion line not with other drugs.
6. Side effects when using Zoldal
During the use of Zoldal, patients may experience some side effects such as:
Common:
Anemia, thrombocytopenia, leukopenia, headache, dizziness, taste disturbances, conjunctivitis, nausea /vomiting, loss of appetite Whole body aches, bone and muscle aches. Uncommon:
Pancytopenia Anxiety, sleep disturbances Cardiac arrhythmias Hypomagnesemia, hypokalemia Usually undesirable side effects (Adverse Drug Reaction (ADR) will disappear when the drug is stopped. Zoldal . If there are rare side effects that are not listed in the package insert for Zoldal . If you have any doubts about the side effects of Zoldal, tell your doctor or pharmacist right away.
7. Precautions when using Zoldal
Zoldal is prescribed by a doctor's prescription, patients do not arbitrarily use the drug without a prescription. In addition, patients need to consult some of the following content before deciding to use Zoldal for treatment.
The patient must be evaluated prior to administration to ensure adequate hydration. Excessive water intake should be avoided in patients at risk of heart failure. Patients receiving zoldal should be carefully monitored for standard metabolic parameters associated with hypercalcaemia, such as measurement of serum calcium, magnesium and phosphate concentrations after initiation of Zoldal therapy. If hypocalcaemia, hypomagnesaemia, or hypophosphataemia occur, short-term additional treatment may be necessary. It is common for people with untreated hypercalcemia to have some degree of renal dysfunction. Zoldal contains the same active ingredient found in Aclasta (zoledronic acid). Patients being treated with drugs should not be treated concurrently with Aclasta. The safety and efficacy of Zoldal for young children have not been established. Renal Impairment: Evidence of impaired renal function should be appropriately evaluated, considering whether the potential benefit of Zoldal treatment outweighs the potential risk. Consideration should be given to the decision to treat Zoldal in patients with bone metastases in order to prevent skeletal-related events because the therapeutic effect begins only after 2-3 months. Factors such as dehydration, pre-existing renal failure, multiple drug cycles or the use of other bisphosphonates, as well as the use of nephrotoxic drugs or intravenous infusions for a shorter duration than prescribed may increase the risk of renal failure. damage kidney function. While the risk is reduced by infusions of 4 mg over 15 minutes, damage to kidney function can still be experienced. Renal damage, progression to renal failure, and dialysis have been reported in patients following initial or single dose administration. An increase in serum creatinine was also observed in some patients receiving Zoldal at doses recommended for prolonged discontinuation to prevent skeletal-related events. Before each dose of Zoldal, it is necessary to assess the serum creatinine concentration in the patient. When initiating therapy in patients with bone metastases with mild to moderate renal impairment, a lower dose of the drug should be used. In patients with evidence of renal damage during treatment, the drug should be reintroduced only when creatinine levels return to within 10% of baseline. Bisphosphonates affect renal function, however, clinical safety data are lacking in patients with severe renal impairment at baseline and there are limited pharmacokinetic data in patients with severe renal impairment at baseline. baseline (ClCR < 30 mL/min), Zoldal is not recommended for patients with severe renal impairment. The safety of Zoldal in pediatric patients with renal failure has not been established. Hepatic Impairment: Because there are only very limited clinical data with Zoldal in patients with severe hepatic impairment, no specific recommendations are made for these subjects. Consider and consult your doctor or pharmacist before taking Zoldal. Mothers need to carefully weigh the benefits and risks for mother and baby before taking Zoldal. Do not arbitrarily use Zoldal without carefully reading the instructions for use and instructions of the doctor to protect the mother and baby. Note: Zoldal is prescribed by a doctor, patients do not arbitrarily use Zoldal without indication.
Please dial HOTLINE for more information or register for an appointment HERE. Download MyVinmec app to make appointments faster and to manage your bookings easily.
